4DMT to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 25-Aug 8:00 AM ET)
4DMT Announces New Employment Inducement Grants
Globe Newswire (Fri, 14-Aug 4:05 PM ET)
Globe Newswire (Thu, 13-Aug 4:05 PM ET)
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
Globe Newswire (Sat, 18-Jul 3:15 PM ET)
Globe Newswire (Tue, 30-Jun 4:05 PM ET)
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
Globe Newswire (Mon, 29-Jun 8:00 AM ET)
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
Globe Newswire (Mon, 29-Jun 8:00 AM ET)
Globe Newswire (Fri, 26-Jun 7:30 AM ET)
FDMT Secures $100 Million in Fresh Funding: New Offering Expands Clinical Ambitions
Market Chameleon (Thu, 6-Nov 3:05 AM ET)
Market Chameleon (Fri, 31-Oct 3:07 AM ET)
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
4D Molecular Therapeutics trades on the NASDAQ stock market under the symbol FDMT.
As of September 11, 2026, FDMT stock price declined to $13.20 with 91,938 million shares trading.
FDMT has a beta of 0.98, meaning it tends to be less sensitive to market movements. FDMT has a correlation of 0.03 to the broad based SPY ETF.
FDMT has a market cap of $729.22 million. This is considered a Small Cap stock.
Last quarter 4D Molecular Therapeutics reported $4 million in Revenue and -$1.04 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.02.
In the last 3 years, FDMT traded as high as $36.25 and as low as $2.24.
The top ETF exchange traded funds that FDMT belongs to (by Net Assets): XBI, VTI, VXF, KOMP, FESM.
FDMT has outperformed the market in the last year with a return of +90.2%, while the SPY ETF gained +18.4%. In the last 3 month period, FDMT beat the market returning +51.4%, while SPY returned +5.7%. However, in the most recent 2 weeks FDMT has underperformed the stock market by returning -11.5%, while SPY returned -0.8%.
FDMT support price is $12.80 and resistance is $14.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FDMT shares will trade within this expected range on the day.